Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen cash
Cash and short-term investments held at the end of each period.
Repligen's cash was $862.98M at Sep 30, 2026. For fiscal 2025 it was $767.63M, up 1.4% from the year before. Over ten years it grew 30.3% a year on average. The highest annual figure on record is $767.63M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $767.63M | +1.4% |
| FY2024 | Dec 31, 2024 | $757.36M | +0.8% |
| FY2023 | Dec 31, 2023 | $751.32M | +43.5% |
| FY2022 | Dec 31, 2022 | $523.46M | -13.3% |
| FY2021 | Dec 31, 2021 | $603.81M | -15.8% |
| FY2020 | Dec 31, 2020 | $717.29M | +33.5% |
| FY2019 | Dec 31, 2019 | $537.41M | +177.3% |
| FY2018 | Dec 31, 2018 | $193.82M | +11.5% |
| FY2017 | Dec 31, 2017 | $173.76M | +41.6% |
| FY2016 | Dec 31, 2016 | $122.68M | +124.9% |
| FY2015 | Dec 31, 2015 | $54.54M | +54.2% |
| FY2014 | Dec 31, 2014 | $35.36M | -42.6% |
| FY2013 | Dec 31, 2013 | $61.62M | +24.2% |
| FY2011 | Mar 31, 2011 | $49.63M | +296.2% |
| FY2010 | Mar 31, 2010 | $12.53M | +148.5% |
| FY2009 | Mar 31, 2009 | $5.04M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $862.98M | +15.3% |
| Q2 FY2026 | Jun 30, 2026 | $810.45M | +14.3% |
| Q1 FY2026 | Mar 31, 2026 | $784.53M | +12.5% |
| Q4 FY2025 | Dec 31, 2025 | $767.63M | +1.4% |
| Q3 FY2025 | Sep 30, 2025 | $748.75M | -4.5% |
| Q2 FY2025 | Jun 30, 2025 | $708.86M | -12.4% |
| Q1 FY2025 | Mar 31, 2025 | $697.23M | -10.7% |
| Q4 FY2024 | Dec 31, 2024 | $757.36M | +0.8% |
| Q3 FY2024 | Sep 30, 2024 | $783.96M | +24.3% |
| Q2 FY2024 | Jun 30, 2024 | $809.15M | +34.0% |
| Q1 FY2024 | Mar 31, 2024 | $780.62M | +51.1% |
| Q4 FY2023 | Dec 31, 2023 | $751.32M | +43.5% |
| Q3 FY2023 | Sep 30, 2023 | $630.78M | +10.0% |
| Q2 FY2023 | Jun 30, 2023 | $603.66M | +1.2% |
| Q1 FY2023 | Mar 31, 2023 | $516.61M | -11.6% |
| Q4 FY2022 | Dec 31, 2022 | $523.46M | -13.3% |
| Q3 FY2022 | Sep 30, 2022 | $573.36M | -7.7% |
| Q2 FY2022 | Jun 30, 2022 | $596.51M | -18.8% |
| Q1 FY2022 | Mar 31, 2022 | $584.64M | -17.8% |
| Q4 FY2021 | Dec 31, 2021 | $603.81M | -15.8% |
| Q3 FY2021 | Sep 30, 2021 | $621.10M | +12.3% |
| Q2 FY2021 | Jun 30, 2021 | $734.33M | +31.0% |
| Q1 FY2021 | Mar 31, 2021 | $711.32M | +32.1% |
| Q4 FY2020 | Dec 31, 2020 | $717.29M | +33.5% |
| Q3 FY2020 | Sep 30, 2020 | $553.30M | +5.9% |
| Q2 FY2020 | Jun 30, 2020 | $560.36M | +157.3% |
| Q1 FY2020 | Mar 31, 2020 | $538.57M | +174.6% |
| Q4 FY2019 | Dec 31, 2019 | $537.41M | +177.3% |
| Q3 FY2019 | Sep 30, 2019 | $522.43M | +174.5% |
| Q2 FY2019 | Jun 30, 2019 | $217.82M | +24.0% |
| Q1 FY2019 | Mar 31, 2019 | $196.14M | +12.8% |
| Q4 FY2018 | Dec 31, 2018 | $193.82M | +11.5% |
| Q3 FY2018 | Sep 30, 2018 | $190.30M | +19.2% |
| Q2 FY2018 | Jun 30, 2018 | $175.61M | +23.1% |
| Q1 FY2018 | Mar 31, 2018 | $173.88M | +33.6% |
| Q4 FY2017 | Dec 31, 2017 | $173.76M | +41.6% |
| Q3 FY2017 | Sep 30, 2017 | $159.67M | – |
| Q2 FY2017 | Jun 30, 2017 | $142.66M | – |
| Q1 FY2017 | Mar 31, 2017 | $130.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $122.68M | – |
See a number that looks wrong?